April 16, 2002

Douglass P. Zipes, M.D., FACC, President American College of Cardiology Heart House 9111 Old Georgetown Road Bethesda, MD 20814-1699

Dear Dr. Zipes:

I am responding to your letter to Chairman Meserve dated January 25, 2002, in which you indicated support for the revised 10 CFR Part 35 and urged the Commission to place the training and experience requirements in effect as soon as possible.

We continue to believe that it is important to issue and begin the process of implementing revised 10 CFR Part 35 in a timely manner. Although Congress permitted the NRC to implement some aspects of the revised rule before reporting to Congress, the Commission chose to await implementation of any portion of the revised rule until the report to Congress had been filed. Having now transmitted a report to Congress, the NRC intends, as it stated to Congress, to submit the revised rule for publication in the Federal Register. As a part of its approach for this final rule on 10 CFR 35, the existing requirements of Subpart J will be retained for a 2-year period after the revised Part 35 becomes effective. During that period, licensees will have the option of meeting the requirements of Subpart J or the requirements in Subparts B and D-H. Such an approach will lead to achieving both the reduction of unnecessary regulatory burden and the maintenance of safety for all medical uses of byproduct material.

NRC staff is proceeding with plans and activities to develop guidance for implementation of Part 35 in a timely manner while seeking stakeholder input. The schedule for these activities, including training for license reviewers and inspectors, is enclosed.

As indicated on the enclosed schedule, activities are already underway to meet these goals. NRC staff has contacted several representatives of stakeholder groups, in both the diagnostic and therapeutic community, to participate in a public planning meeting for the development of guidance specific to diagnostic nuclear medicine and ensure that regulatory guidance is risk-informed and performance-based. The NRC is committed to effecting a smooth transition and implementation of the revised Part 35.

Dr. Douglass P. Zipes

The NRC appreciates your continued interest in 10 CFR Part 35 and the efforts of individuals in your community to work with us in moving forward with a risk-informed, performance-based approach. If you have any further questions, please feel free to contact me.

Sincerely,

## /RA/

Martin J. Virgilio, Director Office of Nuclear Material Safety and Safeguards

Enclosure: Schedule for Part 35 Activities

Dr. Douglass P. Zipes

The NRC appreciates your continued interest in 10 CFR Part 35 and the efforts of individuals in your community to work with us in moving forward with a risk-informed, performance-based approach. If you have any further questions, please feel free to contact me.

Sincerely,

## /RA/

Martin J. Virgilio, Director Office of Nuclear Material Safety and Safeguards

Enclosure: Schedule for Part 35 Activities

This correspondence formulates policy or expands, revises, or interprets policy, involves matters pending Commission decision, contains items relating to the performance of Commission duties and responsibilities, or involves items of high Commission interest.

Similar letter sent to Gary V. Heller, M.D., Ph.D., President, American Society of Nuclear Cardiology

Distribution: IMNS Ticket No. 8150

RGordon/RF OCA r/f CPoland EDO r/f CPaperiello PTressler NMSS Dir. Off. r/f WTravers SECY FCameron

Document Name: C:\ORPCheckout\FileNET\ML020910657.wpd ADAMS PACKAGE ACCESSION NO. ML020560036 ADAMS Accession No.Incoming ML020330081

ADAMS Accession No.Incoming ML020330081			*See previous concurrence	
OFFICE:	RGB:IMNS	RGB:IMNS	RGB:IMNS	Tech Editor
NAME:	RBroseus	AHowe	PHolahan AH for	EKraus
DATE:	3/29/2002	2/ 21/2002	2/ 21/2002	2/15/2002
OFFICE:	OGC*	IMNS/NMSS	D:NMSS	
NAME:	STreby	DCool	MVirgilio	
DATE:	2/ 22/2002	4/ 1/2002	04/16/2002	

OFFICIAL RECORD COPY

Schedule for Part 3	35 Activities	
Planning meeting on development of guidance documents and Public Workshops	March 13 (Completed)	
Publish draft NUREG Vol 9.	Late-March — 60 day comment period	
Publish Revised Part 35.	April	
Conduct public workshop on draft NUREG 1556 Vol 9, with emphasis on therapeutic applications of byproduct material.	April 25	
Conduct public workshop on draft NUREG 1556 Vol 9, with emphasis on diagnostic applications of byproduct material.	April 30	
Develop performance-based / risk-informed inspection guidance.	March — May	
<sup>†</sup> Post inspection guidance to web.	Mid-May	
<sup>†</sup> Public workshop on inspection guidance	June 6	
Finalize guidance, including for inspections.	July	
Publish final guidance (NUREG and guidance for diagnostic nuclear medicine).	August	
Regional training of staff and State representatives.	June — July	
	6 months after date of publication	